| Literature DB >> 19043585 |
Judith D Easterbrook1, Sabra L Klein.
Abstract
Hantaviruses, similar to several emerging zoonotic viruses, persistently infect their natural reservoir hosts, without causing overt signs of disease. Spillover to incidental human hosts results in morbidity and mortality mediated by excessive proinflammatory and cellular immune responses. The mechanisms mediating the persistence of hantaviruses and the absence of clinical symptoms in rodent reservoirs are only starting to be uncovered. Recent studies indicate that during hantavirus infection, proinflammatory and antiviral responses are reduced and regulatory responses are elevated at sites of increased virus replication in rodents. The recent discovery of structural and non-structural proteins that suppress type I interferon responses in humans suggests that immune responses in rodent hosts could be mediated directly by the virus. Alternatively, several host factors, including sex steroids, glucocorticoids, and genetic factors, are reported to alter host susceptibility and may contribute to persistence of hantaviruses in rodents. Humans and reservoir hosts differ in infection outcomes and in immune responses to hantavirus infection; thus, understanding the mechanisms mediating viral persistence and the absence of disease in rodents may provide insight into the prevention and treatment of disease in humans. Consideration of the coevolutionary mechanisms mediating hantaviral persistence and rodent host survival is providing insight into the mechanisms by which zoonotic viruses have remained in the environment for millions of years and continue to be transmitted to humans.Entities:
Mesh:
Year: 2008 PMID: 19043585 PMCID: PMC2584234 DOI: 10.1371/journal.ppat.1000172
Source DB: PubMed Journal: PLoS Pathog ISSN: 1553-7366 Impact factor: 6.823
Summary of Immune Responses in Humans during Hantavirus Infection.
| Categorical Response | Immune Marker | Effect of Infection | Virus Species | In Vitro/In Vivo | Tissue or Cell Type | References |
|
| RIG-I | Elevated | SNV | In vitro | HUVEC, ≤24 h p.i. |
|
| Reduced | NY-1V | In vitro | HUVEC, ≤24 h p.i. |
| ||
| TLR3 | Elevated | SNV | In vitro | HUVEC, ≤24 h p.i. |
| |
| IFN-β | Elevated | PUUV, PHV, ANDV | In vitro | HSVEC, HMVEC-L, ≤24 h p.i. |
| |
| Reduced | TULV, PUUV NSs | In vitro | COS-7 and MRC5 cells, ≤24 h p.i. |
| ||
| IFN-α | Elevated | PUUV, HTNV | In vitro | MФ, DCs, 4 days p.i. |
| |
| No change | HTNV | In vivo | Blood, acute |
| ||
| IRF-3, IRF-7 | Elevated | SNV, HTNV, PHV, ANDV | In vitro | HMVEC-L, ≤24 h p.i. |
| |
| MxA | Elevated | HTNV, NY-1V, PHV, PUUV, ANDV, SNV, TULV | In vitro | MФ,HUVEC,HMVEC-L, 6 h–4 days p.i. |
| |
| MHC I and II | Elevated | HTNV | In vitro | DCs, 4 days p.i. |
| |
| CD11b | Elevated | PUUV | In vivo | Blood, acute |
| |
| CD40, CD80, CD86 | Elevated | HTNV | In vitro | DCs, 4 days p.i. |
| |
| NK cells | Elevated | PUUV | In vivo | BAL, acute |
| |
|
| IL-1β | Elevated | SNV, HTNV | In vivo | Blood, lungs, acute |
|
| IL-6 | Elevated | SNV, PUUV | In vivo | Blood, lungs, acute |
| |
| TNF-α | Elevated | PUUV, SNV, HTNV | In vivo | Blood, lungs, kidney, acute |
| |
| Elevated | HTNV | In vitro | DCs, 4 days p.i. |
| ||
| CCL5 | Elevated | SNV, HTNV | In vitro | HMVEC-L, HUVEC, 12 h–4 days p.i. |
| |
| CXCL8 | Elevated | PUUV | In vivo | Blood, acute |
| |
| Elevated | PUUV | In vivo | Men, blood, acute |
| ||
| Elevated | TULV, PHV, HTNV | In vitro | HUVEC, MФ, 2–4 days p.i. |
| ||
| CXCL10 | Elevated | SNV, HTNV, PHV | In vitro | HMVEC-L,HUVEC, 3–4 days p.i. |
| |
| Elevated | PUUV | In vivo | Men, blood, acute |
| ||
| IL-2 | Elevated | SNV, HTNV, PUUV | In vivo | Blood, lungs, acute |
| |
| Nitric oxide | Elevated | PUUV | In vivo | Blood, acute |
| |
| GM-CSF | Elevated | PUUV | In vivo | Women, blood, acute |
| |
| ICAM, VCAM | Elevated | PUUV | In vivo | Kidney, acute |
| |
| Elevated | HTNV, PHV | In vitro | HUVEC, 3–4 days p.i. |
| ||
| E-selectin | Elevated | PUUV | In vivo | Blood, acute |
| |
|
| IFN-γ | Elevated | HTNV, SNV | In vivo | Blood, CD4+,CD8+, lungs, acute |
|
| CD8+ | Elevated | DOBV, PUUV, HTNV | In vivo | Blood, BAL, acute |
| |
| Virus-specific IFN-γ+CD8+ | Elevated | PUUV, SNV | In vivo | PBMC, acute |
| |
| Perforin, Granzyme B | Elevated | PUUV | In vivo | Blood, acute |
| |
| CD4+CD25+ “activated” | Elevated | DOBV, PUUV | In vivo | PBMC, acute |
| |
| IL-4 | Elevated | SNV | In vivo | Lungs, acute |
| |
|
| “suppressor T cells” | Reduced | HTNV | In vivo | Blood, acute |
|
| IL-10 | Elevated | PUUV | In vivo | Blood, acute |
| |
| TGF-β | Elevated | PUUV | In vivo | Kidney, acute |
| |
|
| IgM, IgG, IgA, IgE | Elevated | All hantaviruses | In vivo | Blood |
|
SNV, Sin Nombre virus; NY-1V, New York-1 virus; PUUV, Puumala virus; PHV, Prospect Hill virus; ANDV, Andes virus; TULV, Tula virus; HTNV, Hantaan virus; DOBV, Dobrava virus.
HUVEC, human umbilical vascular endothelial cells; HSVEC, human saphenous vein endothelial cells; HMVEC-L, human lung microvascular endothelial cells; COS-7, African green monkey kidney fibroblasts transformed with Simian virus 40; MRC5, human fetal lung fibroblasts; MФ, macrophages; DCs, dendritic cells; BAL, bronchoalveolar lavage, PBMC, human peripheral blood mononuclear cells.
Acute infection is during symptomatic disease in patients.
Suppressor T cells likely represent cells currently referred to as regulatory T cells.
Summary of Immune Responses in Rodents during Hantavirus Infection.
| Categorical Response | Immune Marker | Effect of Infection | Virus Species | Host, Tissue or Cell Type | Phase of Infection | References |
|
| TLR7 | Reduced | SEOV | Male Norway rats, lungs | Acute, Persistent |
|
| Elevated | SEOV | Female Norway rats, lungs | Acute, Persistent |
| ||
| RIG-I | Elevated | SEOV | Female Norway rats, lungs | Acute, Persistent |
| |
| Elevated | SEOV | Newborn rats, thalamus | Acute |
| ||
| TLR3 | Elevated | SEOV | Male Norway rats, lungs | Acute, Persistent |
| |
| IFN-β | Reduced | SEOV | Male Norway rats, lungs | Acute, Persistent |
| |
| Elevated | SEOV | Female Norway rat lungs | Acute |
| ||
| Mx2 | Reduced | SEOV | Male Norway rats, lungs | Acute, Persistent |
| |
| Elevated | SEOV | Female Norway rats, lungs | Acute, Persistent |
| ||
| Elevated | HTNV, SEOV | Mice | 3–4 days p.i. |
| ||
| JAK2 | Elevated | SEOV | Female Norway rats, lungs | Acute |
| |
| MHC II | Elevated | PUUV | Bank voles | Genetic susceptibility |
| |
|
| IL-1β | Reduced | SEOV | Male Norway rats, lungs | Persistent |
|
| IL-6 | Reduced | SEOV | Male and female Norway rats, lungs | Acute, Persistent |
| |
| Elevated | SEOV | Male rats, spleen | Acute |
| ||
| TNF-α | Reduced | HTNV | Newborn mice | Acute |
| |
| Reduced | SEOV | Male Norway rats, lungs | Acute, Persistent |
| ||
| Elevated | SEOV | Female Norway rats, lungs | Persistent |
| ||
| CX3CL1, CXCL10 | Reduced | SEOV | Male Norway rats, lungs | Acute, Persistent |
| |
| Elevated | SEOV | Male Norway rats, spleen | Acute |
| ||
| CCL2, CCL5 | Elevated | SEOV | Male Norway rats, spleen | Acute |
| |
| NOS2 | Reduced | SEOV | Male Norway rats, lungs | Acute, Persistent |
| |
| Elevated | SEOV | Male Norway rats, spleen | Acute |
| ||
| Elevated | HTNV | Mouse MФ | 6 h p.i. |
| ||
| VCAM, VEGF | Elevated | SEOV | Male Norway rats, spleen | Acute |
| |
|
| CD8+ | Reduced | HTNV | Newborn mice | Persistent |
|
| Elevated | HTNV | SCID mice | Persistence |
| ||
| Elevated | SEOV | Female Norway rats, lungs | Persistent |
| ||
| IFN-γ | Elevated | SEOV | Female Norway rats, lungs | Persistent |
| |
| Elevated | SEOV | Male Norway rats, spleen | Acute |
| ||
| Elevated | SEOV | Male and female Norway rats, splenocytes | Acute |
| ||
| Elevated | SNV | Deer mice, CD4+ T cells | Acute |
| ||
| Elevated | HTNV | Newborn mice | Acute |
| ||
| Reduced | HTNV | Newborn mice | Persistent |
| ||
| IFN-γR | Elevated | SEOV | Female Norway rats, lungs | Acute, Persistent |
| |
| Reduced | SEOV | Male Norway rats, lungs | Persistent |
| ||
| T cells | Elevated | SEOV | Nude rats | Persistence |
| |
| Elevated | HTNV | Nude mice | Persistence |
| ||
| IL-4 | Reduced | SEOV | Male Norway rats, lungs | Acute, Persistent |
| |
| Elevated | SNV | Deer mice, CD4+ T cells | Acute |
| ||
| Elevated | SEOV | Male and female Norway rats, splenocytes | Acute |
| ||
|
| Regulatory T cells | Elevated | SEOV | Male Norway rats, lungs | Persistent |
|
| FoxP3 | Elevated | SEOV | Male Norway rats, lungs | Persistent |
| |
| TGF-β | Elevated | SEOV | Male Norway rats, lungs | Persistent |
| |
| SNV | Deer mice, CD4+ T cells | Persistent |
| |||
| IL-10 | Reduced | SEOV | Male Norway rats, lungs and spleen | Acute, Persistent |
| |
| Elevated | SNV | Deer mice, CD4+ T cells | Acute |
| ||
|
| IgG | Elevated | SNV | Deer mice | Persistent |
|
| Elevated | SEOV | Norway rats | Persistent |
| ||
| Elevated | HTNV | Field mice | Persistent |
| ||
| Elevated | PUUV | Bank voles | Persistent |
| ||
| Elevated | BCCV | Cotton rats | Persistent |
|
SEOV, Seoul virus; HTNV, Hantaan virus, PUUV, Puumala virus; SNV, Sin Nombre virus; PUUV, Puumala virus; BCCV, Black Creek Canal virus.
MФ, macrophages.
Acute infection is <30 days p.i. and persistent infection is ≥30 days p.i.
Mus musculus, non-natural reservoir host for hantaviruses.
Figure 1Kinetics of Hantavirus Infection in Rodents.
Adapted from Lee et al. [15] and others [12]–[14],[16],[18],[20], the kinetics of relative hantaviral load in blood (red), saliva (green), and lung tissue (blue) and antibody responses (black) during the acute and persistent phases of infection are represented. The amount of genomic viral RNA, infectious virus titer, and/or relative amount of viral antigen have been incorporated as relative hantaviral load. The antibody response is integrated as the relative amount of anti-hantavirus IgG and/or neutralizing antibody titers.